Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a first-in-human clinical study with EPY201 in focal refractory epilepsy.

Next Previous
Trial Profile

A Phase 1/2a first-in-human clinical study with EPY201 in focal refractory epilepsy.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EPY 201 (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 01 Jul 2024 New trial record
  • 10 Jun 2024 According to EpilepsyGTx media release, the company announced the completion of canine biodistribution studies with AAV9 intraparenchymal gene therapy, supporting the planned submission of a clinical trial application for this study.
  • 10 Jun 2024 According to EpilepsyGTx media release, the company is looking forward to initiating a groundbreaking first-in-human study with EPY201, which will be milestone for the company.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top